GRANULESGranules India Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on GRANULES — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 22.0% YoY
- • Profit growth: 53.4% YoY
- • Debt/Equity: 0.30
- • MACD: fresh bullish crossover
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 22.0% YoY
- • Profit growth: 53.4% YoY
- • Debt/Equity: 0.30
- • MACD: fresh bullish crossover
Bear case
- • Dividend yield: 0.18%
- • Price vs EMA21: below
- • Price vs SMA50: below
- • 1-month return: -3.8%
Key risks
- • Dividend yield: 0.18%
- • Price vs EMA21: below
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹27.35). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.